Clinical Trial Update: Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability and pharmacokinetic study of TAK-063 in participants with stable schizophrenia and healthy volunteers has completed and results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• TAK-063 (TAK-063)

Snippet

Sponsor: Takeda | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2016-10-28